Atrium Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Atrium Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RNA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002093101
Board of directors
-
Carsten Boess · DirectorSince 2026
-
Kathleen P. Gallagher · Director · See RemarksSince 2026
-
Sarah Boyce · DirectorSince 2026
-
Simona Skerjanec · DirectorSince 2026
-
Troy Edward Wilson · DirectorSince 2026
-
W. Michael Flanagan · DirectorSince 2026
Board connections
4 of this board's directors also sit on 6 other boards. 6 are in the same sector.
-
Contineum Therapeutics Inc. Same sectorvia Sarah Boyce
-
Immunic Inc. Same sectorvia Simona Skerjanec
-
Kura Oncology Inc. Same sectorvia Troy Edward Wilson
-
OmniAb Inc. Same sectorvia Sarah Boyce
-
Puma Biotechnology Inc Same sectorvia Troy Edward Wilson
-
Rocket Pharmaceuticals Inc. Same sectorvia Carsten Boess
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 18, 2026 | Hoyos Rocio Martin Officer (Chief Strategy Officer) | Shares withheld for tax | −8,320 | $8.95 | $74,464 |
| Sep 18, 2026 | Winslow Brendan R. Officer (Chief Financial Officer) | Shares withheld for tax | −6,742 | $8.95 | $60,341 |
| Sep 18, 2026 | Kathleen P. Gallagher Director, Officer (See Remarks) | Shares withheld for tax | −11,632 | $8.95 | $104,106 |
| Sep 18, 2026 | Kenney Stephanie Officer (See Remarks) | Shares withheld for tax | −2,375 | $8.95 | $21,256 |
| Sep 18, 2026 | Sarah Boyce Director | Shares withheld for tax | −126,418 | $8.95 | $1,131,441 |
| Sep 18, 2026 | W. Michael Flanagan Director | Shares withheld for tax | −22,812 | $8.95 | $204,167 |
| Sep 18, 2026 | Hughes Steven George Officer (Chief Medical Officer) | Shares withheld for tax | −21,459 | $8.95 | $192,058 |
| Sep 18, 2026 | Younis Husam Officer (Chief Scientific Officer) | Shares withheld for tax | −11,216 | $8.95 | $100,383 |
| Apr 20, 2026 | Kenney Stephanie Officer (See Remarks) | Grant or award | +30,000 | — | — |
| Apr 20, 2026 | Hughes Steven George Officer (Chief Medical Officer) | Grant or award | +30,000 | — | — |
| Apr 20, 2026 | Winslow Brendan R. Officer (Chief Financial Officer) | Grant or award | +30,000 | — | — |
| Apr 20, 2026 | Kathleen P. Gallagher Director, Officer (See Remarks) | Grant or award | +102,500 | — | — |
| Apr 20, 2026 | Hoyos Rocio Martin Officer (Chief Strategy Officer) | Grant or award | +30,000 | — | — |
| Apr 20, 2026 | Younis Husam Officer (Chief Scientific Officer) | Grant or award | +30,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Atrium Therapeutics Inc.
How many directors are on Atrium Therapeutics Inc.'s board?
Atrium Therapeutics Inc.'s board has 6 directors: Carsten Boess, Kathleen P. Gallagher, Sarah Boyce, Simona Skerjanec, Troy Edward Wilson and W. Michael Flanagan.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="atrium-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.